ClinicalTrials.gg
RecruitingNCT07323654BREADTHUpdated Oct 6, 2026

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

A Phase 2 interventional study of KT-621 and Placebo in Eosinophilic Asthma, sponsored by Kymera Therapeutics, Inc.. Recruiting at 81 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Kymera Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 6, 2026First sites in Austria, Belgium and Italy10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.

The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

02

Conditions studied

  • Eosinophilic Asthma

Keywords

  • kt-621
  • stat6 degrader
  • stat6
  • targeted protein degrader
  • Phase 2
  • phase 2b
03

In context

Lead sponsor

Kymera Therapeutics, Inc. is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF.
  • Must have a physician diagnosis of asthma for at least 1 year prior to the Screening visit.
  • Must be on a stable regimen of medium- to high- dose inhaled (ICS), in combination with a long-acting β2-agonist (LABA). The regimen may include additional controller medications used for at least 12 weeks, at a stable dose and regimen, with no change in the dose or frequency of administration for at least 4 weeks prior to the Screening visit and between the Screening and Baseline visits.
  • Must have a pre-bronchodilator 40 to 80% of predicted normal at the Screening and Baseline visits, prior to randomization.
  • Must have an ACQ-5 score ≥ 1.5 at the Screening and Baseline visits, prior to randomization.
  • Must have a FeNO level of ≥ 25 ppb at the Screening and Baseline visits.
  • Must have a demonstrated evidence of reversible airway obstruction by post-bronchodilator (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL at Screening.
  • Must have an absolute blood eosinophil count must be ≥ 0.30 × 10\^9/L at Screening.
  • Must have a documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening within the past 52 weeks prior to Screening.
  • Must agree to requirements in compliance with the clinical study and local requirements.
  • Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Must not have any pulmonary disease other than asthma.
  • Must not have had an asthma exacerbation, requiring either treatment with systemic (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening, at any time from 4 weeks prior to the Screening visit up to and including the Baseline visit.
  • Must not have any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, study evaluations, and/or study procedures.
  • Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.
  • Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.
  • Must not have been dosed with any drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
  • Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
  • Must not be a current smoker of nicotine/tobacco as well as non-nicotine products, have a smoking history of ≥ 10 pack years, or use vaping products, including electronic cigarettes. Former smokers with a smoking history of \< 10 pack years and users of vaping or e-cigarette products must have stopped for at least 26 weeks prior to the Screening visit.
  • Must not have a known sensitivity to any of the components of KT-621.
  • Must not be a member of the investigational team or his/her immediate family.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    Group 1: KT-621 Dose 1

    Drug: KT-621

  • Experimental
    Group 2: KT-621 Dose 2

    Drug: KT-621

  • Experimental
    Group 3: KT-621 Dose 3

    Drug: KT-621

  • Placebo comparator
    Group 4: Placebo

    Other: Placebo

Interventions

  • DrugKT-621

    Oral drug

  • OtherPlacebo

    Oral placebo matched to KT-621

06

What researchers measure

Primary outcomes

  1. Change from baseline in pre-bronchodilator FEV1

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Change from baseline in post-bronchodilator FEV1

    Time frame: From baseline to Week 12

  2. Change from baseline in Asthma Control Questionnaire 5-question version (ACQ-5) score

    Time frame: From baseline to Week 12

  3. Change from baseline in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Global Score

    Time frame: From baseline to Week 12

  4. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From baseline through Week 16

  5. Incidence of treatment-emergent serious adverse events (SAEs)

    Time frame: From baseline through Week 16

  6. Plasma concentration of KT-621 derived from plasma concentration time data

    Time frame: From baseline to Week 16

07

Study locations

81 of 81 sites recruiting
  • Kymera Investigative Site
    Lancaster, California 93534, United States
    Recruiting
  • Kymera Investigative Site
    Long Beach, California 90815, United States
    Recruiting
  • Kymera Investigative Site
    Northridge, California 91324, United States
    Recruiting
  • Kymera Investigative Site
    Redding, California 96001, United States
    Recruiting
  • Kymera Investigative Site
    San Francisco, California 94112, United States
    Recruiting
  • Kymera Investigative Site
    Upland, California 91786, United States
    Recruiting
  • Kymera Investigative Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Kymera Investigative Site
    New Haven, Connecticut 06519, United States
    Recruiting
  • Kymera Investigative Site
    Loxahatchee Groves, Florida 33470, United States
    Recruiting
  • Kymera Investigative Site
    Miami, Florida 33126, United States
    Recruiting
  • Kymera Investigative Site
    Miami, Florida 33173, United States
    Recruiting
  • Kymera Investigative Site
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Kymera Investigative Site
    Orlando, Florida 32819, United States
    Recruiting
  • Kymera Investigative Site
    Tampa, Florida 33607, United States
    Recruiting
  • Kymera Investigative Site
    East Point, Georgia 30344, United States
    Recruiting
  • Kymera Investigative Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • Kymera Investigative Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Kymera Investigative Site
    Louisville, Kentucky 40217, United States
    Recruiting
  • Kymera Investigative Site
    Boston, Massachusetts 02114, United States
    Recruiting
  • Kymera Investigative Site
    Chapel Hill, North Carolina 27517, United States
    Recruiting
  • Kymera Investigative Site
    Durham, North Carolina 27705, United States
    Recruiting
  • Kymera Investigative Site
    Toledo, Ohio 43617, United States
    Recruiting
  • Kymera Investigative Site
    Edmond, Oklahoma 73034, United States
    Recruiting
  • Kymera Investigative Site
    Clackamas, Oregon 97015, United States
    Recruiting
  • Kymera Investigative Site
    Philadelphia, Pennsylvania 19140, United States
    Recruiting
  • Kymera Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • Kymera Investigative Site
    Pittsburgh, Pennsylvania 15241, United States
    Recruiting
  • Kymera Investigative Site
    North Charleston, South Carolina 29406, United States
    Recruiting
  • Kymera Investigative Site
    Rock Hill, South Carolina 29732, United States
    Recruiting
  • Kymera Investigative Site
    Chattanooga, Tennessee 37403, United States
    Recruiting
  • Kymera Investigative Site
    Dallas, Texas 75209, United States
    Recruiting
  • Kymera Investigative Site
    Dallas, Texas 75246, United States
    Recruiting
  • Kymera Investigative Site
    McKinney, Texas 75069, United States
    Recruiting
  • Kymera Investigative Site
    Madison, Wisconsin 53792, United States
    Recruiting
  • Kymera Investigative Site
    Buenos Aires, Argentina
    Recruiting
  • Kymera Investigative Site
    Concepción del Uruguay, Argentina
    Recruiting
  • Kymera Investigative Site
    Lobos, Argentina
    Recruiting
  • Kymera Investigative Site
    Mar del Plata, Argentina
    Recruiting
  • Kymera Investigative Site
    Quilmes, Argentina
    Recruiting
  • Kymera Investigative Site
    Rosario, Argentina
    Recruiting
  • Kymera Investigative Site
    San Miguel de Tucumán, Argentina
    Recruiting
  • Kymera Investigative Site
    Vienna, Austria
    Recruiting
  • Kymera Investigative Site
    Brussels, Belgium
    Recruiting
  • Kymera Investigative Site
    Erpent, Belgium
    Recruiting
  • Kymera Investigative Site
    Ghent, Belgium
    Recruiting
  • Kymera Investigative Site
    Liège, Belgium
    Recruiting
  • Kymera Investigative Site
    Berlin, Germany
    Recruiting
  • Kymera Investigative Site
    Leipzig, Germany
    Recruiting
  • Kymera Investigative Site
    Rome, Italy
    Recruiting
  • Kymera Investigative Site
    Bialystok, Poland
    Recruiting
  • Kymera Investigative Site
    Gdansk, Poland
    Recruiting
  • Kymera Investigative Site
    Lodz, Poland
    Recruiting
  • Kymera Investigative Site
    Poznan, Poland
    Recruiting
  • Kymera Investigative Site
    Sosnowiec, Poland
    Recruiting
  • Kymera Investigative Site
    Tarnów, Poland
    Recruiting
  • Kymera Investigative Site
    Trzebnica, Poland
    Recruiting
  • Kymera Investigative Site
    Wroclaw, Poland
    Recruiting
  • Kymera Investigative Site
    Zawadzkie, Poland
    Recruiting
  • Kymera Investigative Site
    Brasov, Romania
    Recruiting
  • Kymera Investigative Site
    Craiova, Romania
    Recruiting
  • Kymera Investigative Site
    Timișoara, Romania
    Recruiting
  • Kymera Investigative Site
    Belgrade, 11000, Serbia
    Recruiting
  • Kymera Investigative Site
    Belgrade, Serbia
    Recruiting
  • Kymera Investigative Site
    Kamenitz, 21204, Serbia
    Recruiting
  • Kymera Investigative Site
    Užice, 31000, Serbia
    Recruiting
  • Kymera Investigative Site
    Bardejov, Slovakia
    Recruiting
  • Kymera Investigative Site
    Košice, Slovakia
    Recruiting
  • Kymera Investigative Site
    Spišská Nová Ves, Slovakia
    Recruiting
  • Kymera Investigative Site
    Gyeonggi-do, South Korea
    Recruiting
  • Kymera Investigative Site
    Seoul, South Korea
    Recruiting
  • Kymera Investigative Site
    Cadiz, Spain
    Recruiting
  • Kymera Investigative Site
    Jerez de la Frontera, Spain
    Recruiting
  • Kymera Investigative Site
    Madrid, Spain
    Recruiting
  • Kymera Investigative Site
    Mataró, Spain
    Recruiting
  • Kymera Investigative Site
    Santander, Spain
    Recruiting
  • Kymera Investigative Site
    Bedford, MK40 2FG, United Kingdom
    Recruiting
  • Kymera Investigative Site
    Birmingham, United Kingdom
    Recruiting
  • Kymera Investigative Site
    Bristol, United Kingdom
    Recruiting
  • Kymera Investigative Site
    Leicester, United Kingdom
    Recruiting
  • Kymera Investigative Site
    London, United Kingdom
    Recruiting
  • Kymera Investigative Site
    Wythenshawe, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 7, 2026
StartActual
Jan 28, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first sites in Austria, Belgium and Italy
Show 10 added (4 Belgium, 3 Argentina, 1 Austria, 1 Italy, 1 South Korea)
  • Kymera Investigative Site · Lobos, Argentina
  • Kymera Investigative Site · Mar del Plata, Argentina
  • Kymera Investigative Site · Quilmes, Argentina
  • Kymera Investigative Site · Vienna, Austria
  • Kymera Investigative Site · Brussels, Belgium
  • Kymera Investigative Site · Erpent, Belgium
  • Kymera Investigative Site · Ghent, Belgium
  • Kymera Investigative Site · Liège, Belgium
  • Kymera Investigative Site · Rome, Italy
  • Kymera Investigative Site · Gyeonggi-do, South Korea
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    10 sites added — first sites in Austria, Belgium and Italy
    Show 10 added (4 Belgium, 3 Argentina, 1 Austria, 1 Italy, 1 South Korea)
    • Kymera Investigative Site · Lobos, Argentina
    • Kymera Investigative Site · Mar del Plata, Argentina
    • Kymera Investigative Site · Quilmes, Argentina
    • Kymera Investigative Site · Vienna, Austria
    • Kymera Investigative Site · Brussels, Belgium
    • Kymera Investigative Site · Erpent, Belgium
    • Kymera Investigative Site · Ghent, Belgium
    • Kymera Investigative Site · Liège, Belgium
    • Kymera Investigative Site · Rome, Italy
    • Kymera Investigative Site · Gyeonggi-do, South Korea

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07323654
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jan 28, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Kymera Medical Director
Contact
clinicaltrials@kymeratx.com
857-285-5300

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KT-621

Start the discussion